Premium
Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer
Author(s) -
Rubens R. D.,
Hayward J. L.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d
Subject(s) - medicine , estrogen receptor , endocrine system , chemotherapy , breast cancer , estrogen , oncology , cytotoxic t cell , cancer , endocrinology , hormone , biology , biochemistry , in vitro
In a consecutive series of 191 patients with advanced breast cancer, the response rate to endocrine treatment was 46/136 (34%) in estrogen receptor positive (ER+) patients, compared with 5/55 (9%) in estrogen receptor negative (ER−) patients (P < 0.01). In a retrospective analysis of 47 patients, the response rate to cytotoxic chemotherapy was 20/33 (62%) for ER+ tumors and 8/14 (57%) for ER−. It is concluded that ER+ tumors have a significantly higher chance of responding to endocrine therapy than do ER− tumors, but that receptor status is not a determinant of response to cytotoxic chemotherapy.